OcuTerra to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)-- OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced the company’s participation in two upcoming investor conferences.

OcuTerra CEO & President Kerrie Brady, BPharm, MS, MBA, will give a fireside chat at BTIG’s Ophthalmology Day on November 29.

BTIG Ophthalmology Day
Session: Fireside Chat
Date & Time: November 29, 2022, 11:30-11:55am ET

Ms. Brady will also participate in the ophthalmology panel at Cantor Fitzgerald’s Medical and Aesthetic Dermatology & Ophthalmology Conference.

Cantor Medical and Aesthetic Dermatology & Ophthalmology Conference
Session: Ophthalmology Panel: Take a Look at What’s in Store for Wet AMD & Related Diabetic Eye Diseases
Date & Time: December 8, 2022, 2:45-3:30pm ET

About OTT166
OTT166 is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, OTT166 selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, OTT166 eye drops have demonstrated preliminary evidence of tolerability and biological activity.

About OcuTerra Therapeutics
OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the [early] progression of disease. Our initial therapeutic candidate, OTT166, administered as an eye drop containing a novel, potent and selective integrin-inhibitor, is in clinical development as an early, non-invasive intervention for diabetic retinopathy, a chronic, progressive disease that is one of the leading causes of vision loss globally. Our goal is to bring transformative treatments to patients and their clinicians who are currently consigned to watch and wait as disease progresses, ultimately requiring medically intensive and invasive therapy. www.ocuterratx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005173/en/